VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 7071 · 116th Congress

Accelerating Access to Critical Therapies for ALS Act

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.

JFR FortenberrySponsor
198 cosponsors · 116 D, 82 R
MQD Quigley KCR Calvert RCR Crawford JCD Crow BFR Fitzpatrick JHR Hill CHR Higgins JND Neguse HRD Rouda DSR Schweikert TSD Sewell AHR Harris SWR Womack MBR Brooks TCR Cole PCR Cook JBD Beatty RDR Davis CFR Fleischmann JGD Golden SKR King ASD Sires MSD Scanlon JVR Van Drew GHR Holding PKR King GMD Meeks JMR Moolenaar CRD Ruppersberger SSR Stivers GSD Stanton MTR Turner WTR Timmons BWR Westerman BBR Babin GCD Cisneros SDR DesJarlais AGD Green JKR Katko RKD Khanna JLD Langevin ELD Luria TMR McClintock TOD O’Halleran CPD Peterson DPD Payne DRR Riggleman DSD Soto RTD Tlaib JBD Brownley JCD Cooper ACD Craig JCD Cunningham ALD Lowenthal TLD Lieu BMD McCollum CMR McMorris Rodgers DMR McKinley CMR Miller LRD Roybal-Allard DSD Scott JSR Smith RWR Weber TYR Yoho CAD Axne PDD DeFazio SDD Davis VGD Gonzalez DLR LaMalfa CLD Lamb SMD Moulton GND Napolitano CPD Pappas JSD Speier ESR Stefanik MWR Waltz MAR Amodei CAD Allred DBR Bacon WCD Clay DCD Cicilline VDD Demings NDR Dunn MDD Dean LFD Frankel GGR Gianforte KHR Hern DKD Kilmer TKR Kelly ALD Lawson JMD McNerney SMD Maloney GMD Meng TMD Malinowski CPD Pingree JRD Raskin BSD Schneider ASD Spanberger BWR Wenstrup ABR Biggs ACD Carson MDR Diaz-Balart JGD Garamendi JHD Huffman DHD Haaland KHD Horn DKD Kildee RKD Kelly FLR Lucas BLR Loudermilk MMR Mullin LMD McBath TRD Ryan JRR Rutherford NVD Velázquez PWD Welch RWR Wittman SWD Wild PAD Aguilar PTD Tonko HGR Griffith FKR Keller END Norton TTR Tiffany JCD Costa TCD Cárdenas TDD Deutch BFR Flores JHD Harder AKD Kim BRD Rush GTR Thompson DWD Wasserman Schultz GBR Bilirakis JHR Hagedorn AKD Kuster DLR Lamborn ASR Smith JWD Wexton ABD Brindisi ADD Delgado JMD McGovern FUR Upton SBD Bishop YCD Clarke DED Evans DJR Joyce RKD Krishnamoorthi MMR McCaul BMR Mast MRD Rose ASR Scott TSD Suozzi SWR Watkins LZR Zeldin RAR Abraham SBR Brooks SCR Chabot SCD Cohen DDD Davis AFR Ferguson RGD Gallego AGR Gonzalez AHD Hastings BHR Huizenga CHD Houlahan WKD Keating KRD Rice ESD Slotkin JHD Hayes BPR Posey GRR Reschenthaler MSR Simpson BWD Watson Coleman BBD Boyle MDD DeSaulnier BLD Lee CMD Maloney PRR Roe JSD Schakowsky ASD Schiff MTD Thompson SLD Lynch SLD Lee JMD Morelle HSD Stevens JVD Vargas RBR Bishop NBD Barragán JDR Duncan APD Pressley ESD Swalwell KCD Clark MGR Garcia DMR Meuser DPD Phillips WSR Steube JWR Wilson

1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

This bill establishes a grant program, as well as a new center within the Food and Drug Administration (FDA), to facilitate access to investigational therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (i.e., ALS, also known as Lou Gehrig's disease, a progressive and fatal disease).

What it does: CRS summary · Introduced in House · Jun 1, 2020

Accelerating Access to Critical Therapies for ALS Act

This bill establishes a grant program, as well as a new center within the Food and Drug Administration (FDA), to facilitate access to investigational therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (i.e., ALS, also known as Lou Gehrig's disease, a progressive and fatal disease).

Specifically, the Department of Health and Human Services (HHS) must award grants for the provision of investigational drugs for ALS and other rapidly progressing neurodegenerative diseases through an expanded access (i.e., compassionate use) program. HHS may award these grants to (1) a small business that is the sponsor of an investigational new drug application, or (2) a participating clinical trial site for such a sponsor.

Additionally, HHS must establish within the FDA a Center of Excellence for Neurodegenerative Diseases. The center shall have duties and authorities similar to those of the FDA's Oncology Center of Excellence, which helps expedite the development of medical products and assists providers in requesting access to investigational drugs.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Accelerating Access to Critical Therapies for ALS Act

Latest action (Jun 1, 2020): Referred to the House Committee on Energy and Commerce.

Policy area: Health · Origin: House · Introduced: Jun 1, 2020

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

No recorded floor vote found.